Join this webinar to see how VLPs move from production and scale-up to serological applications, and what this could mean for your own diagnostic or vaccine development work.
Virus-like particles (VLPs) closely resemble viruses but are non-infectious and contain no viral genetic material, offering a versatile platform for applications across diagnostic and vaccine development.
But how are VLPs produced at scale, and what makes them particularly useful in serological applications?
In this webinar, experts from LGC will explore unmodified VLPs, including flavi-, alpha- and calici-VLPs, taking attendees through key considerations in their manufacture, purification and quality control.
The session will examine the advantages of stable cell line development over transient transfection for raw material production, with a particular focus on at-scale dengue VLP manufacture and preliminary results from production in bioreactors.
The webinar will then move from manufacture to application, presenting data generated using VLPs and exploring their potential as serological capture agents, including in the detection of neutralising antibodies.
RESERVE YOUR PLACE VIA THE FORM NOW
What will you learn?
- How VLPs can improve serology assay performance
- The emerging trends and opportunities in diagnostic assay development
- How native-like VLPs can enhance IgM and IgG detection
- Practical insights from industry experts and put your questions to them during a live Q&A
- New approaches for next-generation diagnostics and serology testing
Meet the expert
Holger Hannemann | Director of R&D, Antigens and Reagents
Holger studied biology at the University of Erlangen, Germany, and earned a PhD studying transcription factors regulating morphological changes in Aspergillus fumigatus and Candida albicans. His postdoctoral studies at the Universities of Idaho and Bristol focused on the molecular and biochemical interactions of human cytomegalovirus and dengue virus with their hosts.
He joined The Native Antigen Company in 2012, where he developed native antigens and introduced recombinant expression technology to the portfolio. Since the acquisition of The Native Antigen Company by LGC in 2020, he has led R&D focused on new antigens and reagents. His team is based in Oxford, UK.
Register now through your Drug Target Review membership.
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
The webinar will be taking place on November 18th 2026
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
